TC 210
A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer
| Principal Investigator | Phase | Penn Study Number | Clinicaltrials.gov ID |
|---|---|---|---|
| Janos Tanyi, MD PhD | 1/2 | UPCC14819 | NCT 03907852 |
Purpose
Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This Phase 1/2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently determine an overall response rate in patients with advanced mesothelin-expressing cancers.
Check Eligibility for this Trial
To inquire about participating in this study, please contact Katie Elkins, 215-615-6740 Katie.Elkins@pennmedicine.upenn.edu